Baylor University Medical Center Proceedings最新文献

{"title":"Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials.","authors":"Majd M AlBarakat, Jehad Feras AlSamhori, Ahmed Abdelaziz, Amr Elrosasy, Mohamad A Elzeftawy, Rana Ahmed Youssef, Rana B Altawalbeh, Mohamed Abuelazm, Basel Abdelazeem","doi":"10.1080/08998280.2025.2491894","DOIUrl":"10.1080/08998280.2025.2491894","url":null,"abstract":"<p><strong>Introduction: </strong>Approximately 360 million women globally experience hot flashes, with varying rates influenced by cultural and racial factors. Vasomotor symptoms (VMS) impact 80% of US women during menopause, with emerging risk factors including high body mass index and African American ancestry. Fezolinetant, an oral neurokinin-3 receptor antagonist, showed promising efficacy in managing VMS. We aimed to comprehensively assess the impact of fezolinetant on VMS in postmenopausal women.</p><p><strong>Methods: </strong>We searched PubMed, Cochrane, Web of Science, SCOPUS, and EMBASE until July 2023 for randomized controlled trials comparing fezolinetant to placebo in women with moderate to severe VMS. Primary outcomes encompassed VMS frequency and severity, and secondary outcomes included treatment effects, quality of life, and safety. Data were collected and analyzed using STATA 17 MP.</p><p><strong>Results: </strong>We included six studies with 3657 patients. Fezolinetant significantly reduced VMS frequency at both 4 weeks (Cohen's d = -0.56; 95% confidence interval [CI], -0.79, -0.34; <i>P</i> < 0.001) and 12 weeks (Cohen's d = -0.34; 95% CI, -0.45, -0.14; <i>P</i> < 0.001). In terms of secondary outcomes, fezolinetant significantly improved health-related functioning and global clinical summary scores, particularly with the 90 mg twice per day dosage. Crucially, there were no statistically significant differences between fezolinetant and placebo concerning the occurrence of any treatment-emergent (odds ratio [OR] = 1.01, <i>P</i> = 0.81) or serious (OR = 1.57, <i>P</i> = 0.90) adverse events.</p><p><strong>Conclusion: </strong>Fezolinetant effectively reduces VMS in postmenopausal women at both 4 and 12 weeks, aligning with previous research. It also improves quality of life, with a promising safety profile. Given fezolinetant's potential for liver enzyme elevations, it is essential to monitor liver function at baseline and regularly thereafter (monthly for the first 3 months and at 6 and 9 months) to ensure patient safety. Further studies with larger sample sizes are needed to confirm these findings.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"535-546"},"PeriodicalIF":0.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing rectal cancer surgery.","authors":"Warren E Lichliter","doi":"10.1080/08998280.2025.2512496","DOIUrl":"https://doi.org/10.1080/08998280.2025.2512496","url":null,"abstract":"","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"387"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights on the rising epidemic of early onset gastric cancer.","authors":"Masen Ragsdale, Catherine H Davis","doi":"10.1080/08998280.2025.2500241","DOIUrl":"10.1080/08998280.2025.2500241","url":null,"abstract":"","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"397-398"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of rectal cancer surgery outcomes in the United States: the influence of hospital volume on rates of sphincter preservation before and after practice standardization.","authors":"Anthony C Waddimba, Wissam J Halabi, Gerald O Ogola, Chad C Griesbach, Katerina O Wells, Walter R Peters, James W Fleshman","doi":"10.1080/08998280.2025.2503653","DOIUrl":"10.1080/08998280.2025.2503653","url":null,"abstract":"<p><strong>Background: </strong>Multiple studies have found hospital-level proctectomy volumes to be associated with quality-of-care outcomes. The Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh) was created in 2011 to spearhead quality standards. We investigated associations of facility-level proctectomy volumes with sphincter-preservation rates, as a rectal cancer surgery quality indicator, across the United States during 14 years before (1998-2011) and 3 years (2012-2014) into the OSTRiCh consortium.</p><p><strong>Methods: </strong>Low anterior and abdominoperineal resections for rectal cancer were identified from the National Inpatient Sample. Multivariable logistic regression with restricted cubic splines was used to test the association between annual proctectomy volumes per hospital and odds of sphincter-preserving resection.</p><p><strong>Results: </strong>We sampled 54,089 proctectomies performed during 1998 to 2014 in 5029 facilities that were 91.9% urban, 66.8% large, and 57.3% teaching hospitals. Recipients were 58.1% male, 70.6% White, 6.6% Black, 46.2% on Medicare, and 43.4% on commercial insurance. Mean age was 63.8 (±12.9) years. Across all study years, an optimum facility-level annual threshold of 30 proctectomies minimized sphincter-sacrificing resections. Analyses restricted to 2012 to 2014 suggested a lower annual optimum of 10 proctectomies per hospital. Higher facility-level proctectomy volume was associated with greater risk-adjusted odds of sphincter preservation in pre-OSTRiCh but not intra-OSTRiCh years.</p><p><strong>Conclusion: </strong>The association between higher facility-level proctectomy volume and sphincter preservation odds during prestandardization years had weakened by the early intra-OSTRiCh years.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"375-386"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avocations.","authors":"Glen Couchman","doi":"10.1080/08998280.2025.2500855","DOIUrl":"https://doi.org/10.1080/08998280.2025.2500855","url":null,"abstract":"","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"398"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes following ventricular tachycardia ablation in patients with end-stage kidney disease: US Renal Data System-based outcome data.","authors":"Het Patel, Ashraf Alzahrani, Lillie Lamont, Ayeesha Kattubadi, David A Hamon, Edward M Powers, Peter D Farjo, Paari Dominic","doi":"10.1080/08998280.2025.2497203","DOIUrl":"10.1080/08998280.2025.2497203","url":null,"abstract":"<p><strong>Introduction: </strong>Data on the outcomes of ablation for paroxysmal ventricular tachycardia (VT) in patients with end-stage renal disease (ESRD) are lacking. This study aimed to identify outcomes of ablation in ESRD patients admitted with paroxysmal VT using the United States Renal Data System (USRDS).</p><p><strong>Method: </strong>All ESRD adult patients who were hospitalized with paroxysmal VT were included from the USRDS registry. Patients were stratified based on ablation treatment. Baseline characteristics were compared using descriptive statistics, and time-to-event analysis was done with a Kaplan-Meier curve. Cox regression analysis was used to assess hazard ratio (HR) for predictors of mortality.</p><p><strong>Results: </strong>A total of 8116 patients were identified. Of them, 688 [8.5%] received a VT ablation. Patients in the ablation group were more frequently younger and of African American descent compared to the no ablation group. VT ablation patients had a higher number of hospitalizations. Both groups had a 5-year mortality >75%; patients in the ablation group had a lower 5-year mortality rate (<i>P</i> < 0.001). Age ≥65 (HR 2.36), White race (HR 1.41), history of congestive heart failure (HR 1.40), and history of coronary artery disease (HR 1.73) were significantly associated with mortality.</p><p><strong>Conclusion: </strong>In selected patients with ESRD and paroxysmal VT, 5-year mortality was lower in those who received an ablation compared to no ablation.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"408-410"},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in mycosis fungoides.","authors":"Kirstin Altman, Oliver Ha","doi":"10.1080/08998280.2025.2505368","DOIUrl":"10.1080/08998280.2025.2505368","url":null,"abstract":"","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"434-435"},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How does mycosis fungoides affect quality of life? Comparative evaluation of the Dermatology Life Quality Index in patients with mycosis fungoides and psoriasis.","authors":"Funda Tamer, Yagmur Aypek, Esra Adisen","doi":"10.1080/08998280.2025.2500853","DOIUrl":"10.1080/08998280.2025.2500853","url":null,"abstract":"<p><strong>Background: </strong>Mycosis fungoides is a chronic cutaneous lymphoma that requires close follow up due to frequent recurrences. Although quality of life has an important role in cancer management, it is generally not evaluated in patients with mycosis fungoides. The Dermatology Life Quality Index (DLQI) questionnaire is a validated skin-specific quality of life index, with answers scored on a scale from 0 to 30. Higher scores are considered as demonstrating a high impact on quality of life. Herein, we compared DLQI scores in patients with mycosis fungoides and psoriasis.</p><p><strong>Methods: </strong>Medical records of patients admitted to the dermatology outpatient clinic between March 2023 and May 2023 were reviewed retrospectively. Afterward, the patients were contacted by phone to answer the questions on the DLQI.</p><p><strong>Results: </strong>This study included a total of 110 patients, 60 with psoriasis and 50 with mycosis fungoides. The median DLQI score was 4 (standard deviation [SD] 8) (range 0-24) in psoriasis patients and 1 (SD 4) (range 0-19) in patients with mycosis fungoides (<i>P</i> = 0.03). Psoriasis affected patients' quality of life more than mycosis fungoides in terms of symptoms and feelings (<i>P</i> = 0.03) and work or school (<i>P</i> = 0.04). However, the median DLQI was similar in patients with mycosis fungoides and psoriasis in terms of daily activities (<i>P</i> = 0.10), leisure (<i>P</i> = 0.28), personal relationships (<i>P</i> = 0.21), and treatment (<i>P</i> = 0.23). Moreover, skin lesions such as plaque and tumor, lesions on extremities, lymph node involvement, itching, pain, and systemic treatment were associated with high DLQI scores in patients with mycosis fungoides.</p><p><strong>Conclusion: </strong>Since various factors such as lesion type, lesion location, symptoms, and treatment significantly affect the DLQI, and DLQI subgroups were affected similarly to patients with psoriasis, we suggest considering DLQI scores when determining the most appropriate treatment option in patients with mycosis fungoides.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"427-433"},"PeriodicalIF":0.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fontan and pregnancy: walking a tightrope.","authors":"Alysha Joseph, Weiyi Tan","doi":"10.1080/08998280.2025.2501904","DOIUrl":"10.1080/08998280.2025.2501904","url":null,"abstract":"","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"497-498"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National prevalence of melanoma: a cross-sectional analysis using the All of Us database.","authors":"Kritin K Verma, Jean E Pizano, Daniel P Friedmann, Cameron E West, Alba Posligua, Michelle B Tarbox, Daniel J Lewis","doi":"10.1080/08998280.2025.2503633","DOIUrl":"10.1080/08998280.2025.2503633","url":null,"abstract":"","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"583-586"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}